Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorazepam for anxiety in adults with advanced life-limiting disease
ACTRN12620001143910Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anxiety disorder comparing Lorazepam with Placebo (2 arms). Primary endpoints: Feasibility of enrollment, Feasibility of early intervention completion and assessment completion and 1 more. Started Apr 2021; status: completed.
02
Drugs
lorazepam
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on ACTRN12620001143910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001143910.